Early Versus Delayed Rehabilitation Intervention in Patients With Lung Cancer

Lung Cancer Clinical Trial

— OVER-CRF  

Official title:

Feasibility of an Early Versus Delayed Rehabilitation Intervention in Patients With Lung Cancer on Cancer-related Fatigue: a Pilot RCT

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06051136
• Other study ID #: OVER-CRF
• Status: Recruiting
• Phase: N/A
• Start date: February 28, 2023
• Est. completion date: September 30, 2024

Study information

• Verified date: July 2023
• Source: Arcispedale Santa Maria Nuova-IRCCS
• Contact: Stefania Fugazzaro, Dr.
• Phone: 0522 296163
• Email: stefania.fugazzaro[@]ausl.re.it
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

In Italy, the incidence of lung cancer for the year 2020 has been estimated at about 41.000 new diagnoses. Patients with lung cancer experience debilitating symptoms caused by the disease itself and cancer treatments, such as dyspnea and fatigue, which reduce physical function and quality of life (QoL). It is estimated that 90% of patients undergoing chemotherapy and 57% of patients undergoing lung resection suffer of Cancer-Related Fatigue (CRF).

Previous studies have shown that educational interventions and aerobic and resistance exercise are effective in improving CRF and QoL in patients with lung cancer. However, to date the optimal dose, mode and timing to deliver the intervention during the care pathway for lung cancer patients is unknown. Tolerability and frequency of cancer treatment could be a barrier to adherence to the intervention. Therefore, this study aims to evaluate the feasibility of a rehabilitation intervention aimed at improving CRF with respect to timing of delivery: early vs delayed rehabilitation in lung cancer patients.

Description:

The primary outcome of the study is to evaluate the feasibility of the experimental pulmonary rehabilitation (RP) program combining the exercise component with the educational component for patients with lung cancer undergoing chemotherapy and/or radiotherapy and/or immunotherapy, delivering RP at different points in the course of their care pathway. The secondary outcome is to evaluate the impact of the intervention on several health outcomes (CRF, physical performance, and QoL) by assessing any differences between early and delayed RP.

The early RP intervention will be delivered in the first three months of cancer treatment, while the same delayed RP intervention will be delivered three months after the start of treatment. Finally, considering the potential beneficial role that exercise on survival of patients with cancer, this study also aims to evaluate this outcome at 12 months after enrollment.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 40
• Est. completion date: September 30, 2024
• Est. primary completion date: March 31, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Newly diagnosed of stage II and III lung cancer (NSCLC) candidates for anticancer therapies (chemotherapy, radiotherapy, immunotherapy, or combinations thereof), associated or not with surgery. In the last case, patients will be included at least 30 days after surgery.

• Prognosis = 12 months

• At least 18 years old

• Recruited from the pneumology, oncology, radiotherapy, and physical medicine and rehabilitation unit of the Azienda Unità Sanitaria Locale - IRCCS of Reggio Emilia

• Willing and able to give written informed consent

Exclusion Criteria:

• Clinical disorders that contraindicate participation in a moderate exercise program (e.g. preexisting severe physical disabilities, major cognitive or sensory deficits, severe psychiatric disorders, language barrier, etc.).

• NSCLC stage IV

• Patients who are candidates for surgery alone

• Patients who are candidates for neoadjuvant therapy

Related Conditions & MeSH terms

• Lung Cancer
• Lung Neoplasms

Intervention

Behavioral:
• Pulmonary rehabilitation
The RP intervention consists in 8 sessions supervised by the physiotherapist weekly or biweekly and 2 therapeutic education group meetings on the importance of exercise and CRF management, over the 3 months of intervention. The RP comprise exercise program performed autonomously at home. Both the outpatient and the autonomously home-based exercise sessions comprise aerobic, resistance and respiratory exercise. The exercise program is individualized and can be delivered in telerehabilitation.

Locations

Country	Name	City	State
Italy	Azienda Unità Sanitaria Locale - IRCCS di Reggio Emilia	Reggio Emilia

Sponsors (1)

Lead Sponsor	Collaborator
Arcispedale Santa Maria Nuova-IRCCS

Country where clinical trial is conducted

Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Feasibility - Adherence rate to the outpatient RP sessions	The number of patients adhering to at least 70% of outpatient RP sessions scheduled for the relative allocation group will be recorded.	At 3 and 6 months after baseline
Secondary	Recruitment rate	The recruitment rate will be estimated with the sample rate calculated as the ratio of the number of patients who partecipate to the study to the number of patients to whom the study is proposed.	At baseline
Secondary	Dropout rate	Number of treatment failures, their causes, and number of sessions conducted	At 3 and 6 months after baseline
Secondary	Cancer-related fatigue (CRF)	CRF will be measured with The Functional Assessment of Chronic Illness Therapy - Fatigue Scale (FACIT-F). The score ranges from 0 to 52. Higher score represents less fatigue experienced by patient. The minimum clinically significant difference for the FACIT-F scale has been estimated at 3 points.	At baseline, at 3, 6, and 12 months after baseline
Secondary	Quality of life (QoL)	QoL will be measured by EORTC- QLQ-C30 questionnaire. The QLQ-C30 consists of 30 items, which assess various dimensions of HRQL: five scales of functioning (physical, role, emotional, cognitive and social), three scales assessing symptoms (fatigue, pain and nausea) and a global measure of health status. The remaining six single-question scales assess symptoms: dyspnea, loss of appetite, sleep disorders, constipation and diarrhea, and the perceived economic impact of treating the disease. High scores indicate better HRQL for global health status and functioning scales, but worse symptoms. The minimum clinically significant difference for the EORTC QLQ-C30 scale was estimated to be between 5 and 10 points.	At baseline, at 3, 6, and 12 months after baseline
Secondary	Physical performance	Physical performance will be neasured by six minute walk test (6MWT). The 6MWT consists of measuring the distance covered in six minutes. Saturation, heart rate, respiratory and muscle fatigue and the number of stops are also releved at both the start and finish. The minimum clinically significant difference for the 6MWT in lung cancer patients was estimated to be 42 m.	At baseline, at 3 and 6 months after baseline
Secondary	Adherence to the exercise home-based sessions	Number of exercise home-based sessions performed by each patient	At baseline, at 3 and 6 months after baseline
Secondary	Physical activity level	Physical activity level will be measured by the International Physical Activity Questionnaire - Short Form (IPAQ-SF). IPAQ-SF is a questionnaire used to estimate the amount of physical activity during the previous 7 days. Weekly frequency and average duration of vigorous and moderate physical activity and walking (regardless of whether during work or leisure time) and the number of daily hours spent sitting are asked. In addition, to assess the level of physical activity performed, IPAQ uses METs (Metabolic Equivalent Tasks).	At baseline, at 3, 6, and 12 months after baseline
Secondary	Adverse events	Recording of adverse events related to the exercise intervention during the 6-month intervention period (falls, fractures, muscle pain, exertional dyspnea, acute inflammation of joints stressed in the rehabilitation program, hematomas, etc.).	At 3, 6, and 12 months after baseline
Secondary	Survival		At 12 months after baseline